Valuation: Evaxion A/S

Market Cap 25.02M 22.4M 20.88M 18.94M 35.72M 2.39B 35.94M 251M 98.23M 1.23B 93.99M 91.91M 3.97B P/E 2026 *
-75x
P/E 2027 * -200x
Enterprise Value 25.02M 22.4M 20.88M 18.94M 35.72M 2.39B 35.94M 251M 98.23M 1.23B 93.99M 91.91M 3.97B EV / Sales 2026 *
-
EV / Sales 2027 * 5.36x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day-2.28%
1 week-4.76%
Current month-8.54%
1 month-4.15%
3 months-5.36%
6 months-25.74%
Current year-37.11%
1 week 2.99
Extreme 2.99
3.25
1 month 2.99
Extreme 2.99
3.35
Current year 2.77
Extreme 2.77
5.48
1 year 2.77
Extreme 2.77
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 2025-11-23
Corporate Officer/Principal 49 2008-08-10
Director of Finance/CFO 53 2024-10-31
Director TitleAgeSince
Chairman 58 2020-11-24
Director/Board Member 56 2017-12-31
Director/Board Member 68 2021-05-24
Date Insider Type Main position Quantity % Market Cap. Importance
4/16/26 Other

Director

2,376 0.0006%
3/18/26 Other

Chief Financial Officer

645,750 0.1549%
3/18/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-4.76%-49.15%-92.72% 25.6M
+0.03%-5.67%+50.74%+76.76% 70.61B
+0.66%-9.75%+6.97%+52.62% 51.01B
+0.31%-0.14%+8.84%+32.99% 48.1B
+0.90%-1.46%+32.32%+32.69% 42.78B
+2.21%-6.61%+302.05%+701.45% 40.67B
-1.15%-3.11%+9.47%+98.83% 40.3B
+0.45%-1.20%+9.11%+43.54% 30.59B
-2.23%-4.96%+39.06%+6.04% 28.16B
-1.16%-1.84%-6.09%-11.99% 24.36B
Average -0.23%-3.00%+40.33%+94.02% 37.66B
Weighted average by Cap. +0.15%-2.97%+52.15%+118.99%

Financials

2026 *2027 *
Net sales - 4.67M 4.18M 3.9M 3.54M 6.67M 446M 6.71M 46.84M 18.33M 230M 17.54M 17.15M 741M
Net income -15.56M -13.93M -12.99M -11.78M -22.22M -1.49B -22.36M -156M -61.09M -768M -58.45M -57.16M -2.47B -11.81M -10.57M -9.86M -8.94M -16.86M -1.13B -16.97M -118M -46.38M -583M -44.37M -43.39M -1.88B
Net Debt - -
Projected Income Statement - Annual - Evaxion A/S
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
26-10-12 US$3.000 -2.28% 60,820
26-10-09 US$3.070 +0.66% 27,855
26-10-08 US$3.050 -3.48% 63,967
26-10-07 US$3.160 0.00% 21,750
26-10-06 US$3.160 +0.32% 35,874
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Evaxion A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.000USD
Average target price
11.25USD
Spread / Average Target
+275.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evaxion A/S
  1. Stock Market
  2. Stocks
  3. EVAX Stock